



DAVID COLLINS
Le**kaemia**
FOUNDATION
OF TASMANIA INC.

Annual Report 2021

“Your help is our hope”



Annual Report 2021

“Your help is our hope”

“Your help is our hope”

The David Collins Leukaemia Foundation of Tasmania Inc.
is a Tasmanian organisation dedicated solely
to the care and cure of Tasmanians
living with leukaemia, lymphoma
and related blood disorders.
All money raised stays in Tasmania.

Excerpts from this publication may be
reproduced, with appropriate acknowledgement,
as permitted by the Copyright Act.

Published May 2022
Printed by Tadpac +61 6272 5000
ISSN 1838-823X

Contents

Office Bearers and Committee Members, Year Ended 31st December 2021	6
President's Report.....	7
Our Patrons	8
Forty-one Years of Achievements 1980 - 2021	9
Research Report 2021	12
Professional Development Award Reports 2021	12
Haematology Trials Data Management Report 2021	13-14
Paediatric Oncology Clinical Trials Report 2021	15-18
Finance.....	19

David Collins Leukaemia Foundation of Tasmania Inc.
Office Bearers and Committee Members
Year Ended 31st December 2021

Patron:	Her Excellency Professor The Honourable Kate Warner AC (January-June) The Honourable Barbara Baker AC (June-December) Governors of Tasmania
President:	Mrs D Tuck OAM
Vice President:	Prof G Woods
Secretary/Public Officer:	Mrs A Ogilvie
Treasurer:	Mrs L Docking
Committee:	Dr K Marsden, Mr G Petterd Mrs W Snell
Life Members:	The late Mrs B Collins The late Mr N Deane Dr M Baikie Mrs J Balon Mrs A Piaszczyk

President's Report

It is with pleasure that I present the President's Report for 2021.

This year's Annual Report reflects the ongoing impact of COVID-19 restrictions and the challenges we have all coped with through these unpredictable times.

The committee met for face-to-face meetings at private homes, rather than in public facilities. The Foundation continued providing support to the Tasmanian community with patient support. Professional development awards were put on hold due to the travel restrictions for health care workers. It is hoped that this very beneficial award system recommences once education and travel opportunities become available.

Support for patients during their illness continued to be provided with financial support in meeting commitments associated with their illnesses which amounted to \$16,869. We have assisted in co-payments for accommodation and living expenses for Tasmanian patients while receiving treatment in Hobart, Victoria, South Australia and Queensland. The monetary amount we have allocated for patient assistance has once again increased since last year. Our future budgeting includes ongoing and increased commitment to this important aspect of patient support.

Funding for the Paediatric Clinical Trials Centre at Royal Hobart Hospital ensured that children can participate in national trials in Tasmania coordinated by A/Prof John Heath, A/Prof Rosemary Harrup and Dr Anna Johnston. In the past Tasmanian children only had access to clinical trials by travelling to Victoria. We have also supported the Adult Haematology Clinical Trials at the Royal Hobart Hospital for patients with blood diseases in Tasmania. The information then becomes part of a nationwide repository of information on treatments and outcomes.

During 2021 the members of the Foundation mourned the loss of our inaugural President, Mr Norman Deane OAM. Norm chaired the first general meeting prior to the Foundation becoming incorporated. His involvement continued as President for several years and then as an active committee member/public officer over many decades. We are indebted to both Norm and his wife Jean for their devotion to continue the goals of the Foundation. In recognition of all his work, Norm Deane was made a Life Member of the Foundation. Condolences were sent to Jean and her family.

The Foundation appreciates the work undertaken by Emma Sells and Associates - an accountant and bookkeeping firm and particularly thank Emma and Sidney for their service.

I would also like to acknowledge the work of the Committee members for their continued commitment in assisting me in ensuring that the Foundation continues to support patients in Tasmania with leukaemia and other blood diseases and those caring for the patients, mindful of responsible financial management.

A thank you must also be extended to the volunteers around the state who monitor our donation containers and diligently deposit monies into our bank account. We are very grateful for your commitment.

During the year our Patron Her Excellency Professor the Honourable Kate Warner AC completed her term as Governor of Tasmania. The committee thanked Kate Warner for her years of Patronage of the Foundation and welcomed Her Excellency the Governor Barbara Baker AC to her new position. She has very kindly accepted our invitation to fulfil the role of Patron of the Foundation.

Thank You

Deirdre Tuck OAM

President, David Collins Leukaemia Foundation of Tasmania

Our Patrons

1980 - 1994 Sir Donald Trescowthick

1995 - 2004 Dr Margaret Baikie

2005 - 2021 The Governors of Tasmania

Forty-one Years of Achievements 1980 - 2021

For each of its 41 years the Foundation has had significant achievements.

Statewide Button Days	Research Grants	Professional Development Awards
Approximately \$400,000	More than \$2 million	Approximately \$100,000

Yearly Achievements

- 1980 Incorporated
- 1981 Presented research grant of \$12,128 and first button day raised \$1,466
- 1982 Research grants totalled \$30,000 and \$5,000 to oncology services
- 1983 Fundraising target of \$80,000 and achieved \$90,348
- 1984 Formation of North West Group
- 1985 Purchased David Collins House
- 1986 Car donated by Mr R Baker raffle raised \$23,000
- 1987 Publication of "Kristy's Book"
- 1988 First statewide Button Day
- 1989 Roger Scott's "Walk for Life" raised \$12,978
- 1990 Progressive fundraising exceeded \$1,000,000
- 1991 Committed \$10,000 to establish Tasmania Bone Marrow Registry
- 1992 Formation of Northern Group based in Launceston
- 1993 Northern Group raised \$5,827
- 1994 Bi-annual statewide meetings introduced
- 1995 Research grants > \$60,000 plus \$12,000 to Bone Marrow Registry
- 1996 Progressive fundraising exceeded \$1,600,000
- 1997 Established "Special Purpose Investment Fund" of \$502,959
- 1998 \$10,000 in equipment presented to the Royal Hobart Hospital
- 1999 North West Group raised a record of \$9,500 for the year

- 2000 Research grants exceeded \$95,000. Became affiliated with the Cancer Council of Tasmania
- 2001 \$11,500 refurbishment of David Collins' House
- 2002 Tom Goninon walked from Wynyard to Hobart to raise \$23,000 in memory of his grandson
- 2003 Joint DCLF/LFA \$8,000 grant to fund Tasmanian Bone Marrow Transplant Support Group
- 2004 Professional Development Awards for Health Care Workers
- 2005 Appointment of first employee as part time Executive Officer
- 2006 Beverley Collins, Norm Deane and Dr Margaret Baikie - Life Members
- 2007 Comalco sponsored refurbishment of bathroom at David Collins House
- 2008 Income from investments and other fundraising totalled \$106,621
- 2009 Purchased equipment valued at \$44,000 for hospitals throughout Tasmania and progressive fundraising exceeded \$3,000,000
- 2010 Reception at Government House to celebrate 30 years and entered partnership with Ponting Foundation
- 2011 Increased "Special Purpose Fund" to \$750,000
State amount of \$22,067 collected on Button Day highest ever
Committed \$80,000 for redevelopment of Oncology Day Centre at St John's Calvary Healthcare and named "David Collins Suite"
- 2012 \$21,075 for three treatment chairs Outpatients Oncology RHH. Blessing and Opening by Archbishop Doyle AM DD of the David Collins Suite Oncology Day Centre, St John's Calvary Health Care Tasmania
- 2013 Joan Balon presented with Life Membership
Provided Accuvein hand held vein illumination systems to St John's, RHH, LGH and NW Regional Hospitals Oncology Wards; \$7,000 each
Provided \$22,000 for 3 x Treatment Chairs to new Oncology Outpatients Unit, RHH
Granted \$45,000 for leukaemia research
Financed Haematology Cancer Care Coordinator at the RHH
- 2014 \$92,000 expenditure for major renovations to David Collins House
Purchased dining table and chairs for Cancer Support Centre, RHH
Agreed to support Haematology Cancer Support Coordinator for a further two years at RHH
\$30,000 towards leukaemia research at the University of Tasmania
- 2015 Review financial management, investments, introduce online banking for 3 years and provided a record \$7,685 for Patient Care and Support

- 2016 Grant \$150,000 to University of Tasmania for DCLFT Elite Research Scholarship “Epigenetic and transcriptional regulation of leukaemia”. \$20,302 to RHH for Data Manager Haematology Cancer Care Registries for Tasmanian input into National Register
- 2017 Grant \$105,000 to RHH to fund Clinical Trials Officer for Childhood Leukaemia and Lymphoma in Tas. Sold DC House and invested proceeds to assist with patient care and leukaemia projects
- 2018 Reviewed Rules of Association, retaining original objects and purposes of the Association and clarifying. Updated the objects and purposes with the current day practices to ensure compliance with principle objects and purposes of the Association. Supported Cancer Care Coordinator at Calvary St Johns Hospital for a further year
- 2019 Decreased size of Committee, increased commitment to patient care and support, cumulative amount awarded for Professional Development Awards = \$90,025
- 2020 Despite COVID -19 restrictions, almost \$14,0000 was provided for patient support
- 2021 Patient support and funding to assist clinical trials were the major activities

Research Report – 2021

No reports for 2021

Professional Development Award Reports 2021

No reports for 2021

Haematology Trials Data Management Report

(January 2021 - June 2021)

Haematology Trials Data Management

HAEMATOLOGY SNAPSHOT: JUN 2021


57 Trials:

25 trials (inclusive of 5 registries) open to recruitment;
32 trials closed to recruitment (with patients in follow-up activity);
15 trials starting up.


266 Haematology Patients:

45 patients in active treatment;
49 patients in follow-up;
172 registry patients.


Trials (Total): 53



Actively recruiting trials: 25



Patients: 255



David Collins Leukaemia Foundation (Tas) Report 1 Jan 2021- Jun2021

(Report generated 20Sep2021)

Current Haematology Registries

We currently manage 6 haematology registries, all of which capture information across several disease streams:

Malignant Haematology

- Lymphoma and Related Diseases Registry (LRDR)
- Myeloma and Related Diseases Registry (MRDR)
- National Blood Cancer Registry (NBCR)
- Follicular Lymphoma prognostics registry

Non Malignant Haematology

- 'Genzyme' Gaucher Disease Registry
- Aplastic Anaemia Registry

Current Haematology Trials

We have 25 actively recruiting haematology trials, across several treatment lines and tumour streams (current enrolling list at **Attachment 1**), and 32 trials in follow-up. With the advancements in the treatment for haematologic cancers, patients are remaining on clinical trials for longer periods of time, all of which requires significant patient follow-up and data management.

We have 15 new haematology trials due to commence in 2021-2022

Phase 1 clinical trials focus on finding the highest dose of a new treatment that can be safely given to a patient without causing severe side effects. Phase 1 trials offers access to treatments not normally accessed by Tasmanian residents. The Royal Hobart Hospital is participating more in phase 1 clinical trials. Site currently has 4 phase 1 haematology clinical trials open to recruitment.

The Importance of Clinical Registries and Quality Trial Data

Clinical Trials and Registries play an important role in the provision of quality patient care and the development of novel therapeutic options. The funding provided by the David Collins Leukaemia Foundation continues to play an important role in managing this capability: to ensure the best possible options are provided to Tasmanian patients.

The additional resources provided by the David Collins Leukaemia Foundation (Tas) have been crucial in maintaining the high quality of our current service provision. We would like to express our gratitude for your continuing support of haematology clinical trial activity in Tasmania.

Haematology Trials Data Management Report

(June 2021 - December 2021)

Haematology Trials Data Management

HAEMATOLOGY SNAPSHOT: JUN 2021


61 Trials:

29 trials (inclusive of 5 registries) open to recruitment;
32 trials closed to recruitment (with patients in follow-up activity);
17 trials starting up.


263 Haematology Patients:

46 patients in active treatment;
24 patients in follow-up;
171 registry patients.


Trials (Total): 61



Actively recruiting trials: 29



Patients: 263



David Collins Leukaemia Foundation(DCLF) (Tas) Report July 2021- Dec 2021

(Report generated 9th March 2022)

Current Haematology Registries

We currently manage 6 haematology registries, all of which capture information across several disease streams:

Malignant Haematology

- Lymphoma and Related Diseases Registry (LRDR)
- Myeloma and Related Diseases Registry (MRDR)
- National Blood Cancer Registry (NBCR)
- Follicular Lymphoma prognostics registry

Non Malignant Haematology

- 'Genzyme' Gaucher Disease Registry
- Aplastic Anaemia Registry

Current Haematology Trials

We have 29 actively recruiting haematology trials, across several treatment lines and tumour streams (current enrolling list at **Attachment 1**), and 32 trials in follow-up. With the advancements in the treatment for haematologic cancers, patients are remaining on clinical trials for longer periods of time, all of which requires significant patient follow-up and data management.

We have 17 new haematology trials due to commence in 2022-2023

Phase 1 trials offers access to treatments not normally accessed by Tasmanian residents. The Royal Hobart Hospital is participating more in phase 1 clinical trials (4 current and 5 in submission).

The Importance of Clinical Registries and Quality Trial Data

Clinical Trials and Registries play an important role in the provision of quality patient care and the development of novel therapeutic options. The funding provided by the DCLF continues to play an important role in managing this capability which benefits not only Tasmanian but also patients at a national and international level.

There have been multiple presentations at conferences and papers published based on data from the LRDR and MRDR (including from Tasmanian patients). The number of collaborations with international colleagues is also growing. An example (among many) is a recent publication in Bone Marrow Transplant in real world outcomes of autologous transplantation in myeloma .

The additional resources provided by the David Collins Leukaemia Foundation (Tas) have been crucial in maintaining the high quality of our current service provision. We would like to express our gratitude for your continuing support of haematology clinical trial activity in Tasmania.

Paediatric Oncology Clinical Trials Report 2021



Tasmanian Health Service
PAEDIATRIC SERVICES

**TASMANIAN
HEALTH
SERVICE**

20 January 2022

Ms Deirdre Tuck

President

David Collins Leukaemia Foundation of Tasmania

Dear Deirdre:

Re: Follow up report for Research Grant (2017 - 2021)

The establishment of an evidence based clinical service and clinical trials program for Tasmanian children with leukaemia / lymphoma

Thank you for your generous funding and support from 2017-2021 for clinical research undertaken within the Paediatric Oncology Division, Department of Paediatrics at the Royal Hobart Hospital. We wish to sincerely thank you for your financial support, which enabled the development of Paediatric Oncology Research and has directly improved the health outcomes of Tasmanian Paediatric and AYA patients.

We would like to report on the status of paediatric leukemia research following the completion of the Research Grant program as follows.

All seven patients enrolled in the EuroNet-PHL-C2 treatment trial are in the follow up phase and have all responded well to their treatment. The Royal Hobart Hospital is also meeting all reporting and audit requirements.

The Minimal Residual Disease (MRD) testing and leukaemia subtyping registry is open for recruitment and we are ready to assess eligible patients to record disease biology, MRD responses and clinical outcomes.

Patients are currently enrolling in the Australian Cardio-Oncology Register (ACOR) registry for paediatric patients who have been exposed to cardiac toxic chemotherapy. Dr Samantha Rose is collecting historical data for the study, which is also open for recruitment.

We are also enrolling patients in a study on Vitamin D and Vitamin D Receptor Polymorphisms in Childhood Cancer patients. Dr Elizabeth Man is lead investigator on the project.

Dr Elizabeth Man and Dr Samantha Rose are both being mentored by Prof John Heath in their respective studies. This is a development for Leukemia research in Tasmania, with the expertise of clinical staff expanded and enhanced through research and training.

The Zero 2 Access study will be open by June 2022 and aims to profile all cancer patients across Australia. This will be available for all Tasmanian children newly diagnosed with a leukaemia / lymphoma.

The Royal Hobart Hospital continues to work with the Royal Children's Hospital to become an affiliate of the Children's Oncology Group. Covid 19 and staff movements at the Royal Children's Hospital have delayed completion, however membership has been approved in principle.

At the 2021 election The Tasmanian Liberal Party promised additional funding for Paediatric Oncology Trials. This money has been received and will have a significant impact on trial activity with the potential for expanded leukaemia studies and access to treatments for Tasmanian patients.

All clinical trials open or in preparation have been listed in Appendix A.



Professor John A Heath

MBBS (Hons), BVSc (Hons), MSc(Harvard), PhD, FRACP

Paediatric, Adolescent and Young Adult Oncologist

Women's, Adolescent and Children's Services (WACS)

Royal Hobart Hospital, THS

48 Liverpool Street, Hobart, Tasmania, Australia 7000

Tel +61 3 6166-7989

Trial Listing

The following table summarises the trials open or currently in development.

Trial	Details	Status
Leukaemia Presentation Patterns	Leukaemia Presentation Patterns in Children. Geographic and Ethnic Differences. A Retrospective Review of Presentation Features and Outcomes in Patients Diagnosed in Australia.	Complete
EuroNet-PHL-C2	Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	Closed to recruitment
Molecular Neuropathology 2.0	Increasing diagnostic accuracy in paediatric neurooncology	Closed to recruitment
North Study	A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma	Closed to recruitment
AIM-BRAIN	Access to Innovative Molecular Diagnostic PROFiling for Paediatric Brain Tumours	Open
NB-SCI Registry	Prospective Study Registry of Peripheral Neuroblastic Tumours presenting with Spinal Canal Involvement (SCI)	Open
ACOR	Australian Cardio-Oncology Register	Open
COVID 19 Surveillance Study	A multicentre study of SARS-CoV-2 infection in children with cancer, immunodeficiency or following stem cell transplant	Open
TiNT	A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas	Open

MRD Registry	Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research	Open
Vitamin D	An observation of Vitamin D deficiency and insufficiency in children newly diagnosed with a malignancy in Tasmania	Open
SJMB12	A Clinical and Molecular Risk Directed Therapy for Newly Diagnosed Medulloblastoma	Open
LCH IV	International Collaborative Treatment Protocol for Children and Adolescents with Langerhans's Cell Histiocytosis	At RHH Executive for approval
ZERO 2.0	Precision Medicine for Every Child with Cancer	In development

Financial Statements

David Collins Leukaemia Foundation of Tasmania Inc
ABN 24 819 325 355
For the year ended 31 December 2021

Prepared by Emma Sells & Associates

Contents

3	Report of Committee
4	Profit and Loss Statement
5	Appropriation Statement
6	Balance Sheet
7	Notes to the Financial Statements
9	Officer Bearers & Committee
10	Committee's Report

Report of Committee

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

True and Fair Certification by Members of The Committee

In accordance with a resolution of the committee of David Collins Leukaemia Foundation of Tasmania Incorporated, the members of the committee declare that:

1. The financial statements as set out is present a true and fair view of the financial position of David Collins Leukaemia Foundation of Tasmania Incorporated as at 31 December 2021 and its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements and the requirements of the Associations Incorporations Act; and
2. At the date of this statement, there are reasonable grounds to believe that David Collins Leukaemia Foundation of Tasmania Incorporated will be able to pay its debts as and when they fall due.

This statement is signed for and on behalf of the committee by:

Signed: 
Deirdre Tuck (Mar 31, 2022 LE 32 GMF+11)

President: Deirdre Tuck

Signed: 
Annette Ogilvie (Mar 18, 2022 01:59 GMF+11)

Secretary: Annette Ogilvie

Dated: Mar 21, 2022

Profit and Loss Statement

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

	2021	2020
Income		
Donations	1,711	4,522
Tin Collections	2,094	2,215
Interest Income	4,123	25,889
Total Income	7,928	32,625
Gross Surplus	7,928	32,625
Expenditure		
Accounting Fees	2,980	1,692
Audit Fees	1,000	1,800
Bank Fees	14	-
Capital Donation	55,132	55,302
Computer Expenses	784	444
Filing Fees & Permits	175	-
Insurance	1,788	1,960
Patient Care	16,869	13,796
Printing & Stationery	538	354
Professional Development Awards	409	-
Sundry Expenses	175	255
Telephone	-	286
Travel & Accommodation	-	91
Total Expenditure	79,864	75,980
Current Year Surplus/ (Deficit) Before Income Tax Adjustments	(71,937)	(43,355)
Current Year Surplus/(Deficit) Before Income Tax	(71,937)	(43,355)
Net Current Year Surplus After Income Tax	(71,937)	(43,355)

The accompanying notes form part of these financial statements. These statements should be read in conjunction with the attached compilation report.

Appropriation Statement

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

	NOTES	2021	2020
Retained Earnings after Appropriation			
Profit/(Loss) Before Taxation		(71,937)	(43,355)
Retained Earnings at Start of Year		1,790,757	1,834,112
Retained Earnings After Appropriation		1,718,821	1,790,757

The accompanying notes form part of these financial statements. These statements should be read in conjunction with the attached compilation report.

Balance Sheet

David Collins Leukaemia Foundation of Tasmania Inc As at 31 December 2021

	NOTES	31 DEC 2021	31 DEC 2020
Assets			
Current Assets			
Cash Assets			
CBA Business Account #1089		10,562	8,467
NAB Business Account #5839		26,032	35,322
NAB Business Account #6917		11,785	1,660
Total Cash Assets		48,379	45,450
Receivables			
Accruals		3,021	7,870
Total Receivables		3,021	7,870
Other			
Fixed Deposits - General Purpose		15,182	15,158
Fixed Deposits - Special Purpose		1,655,219	1,723,805
Total Other		1,670,401	1,738,963
Total Current Assets		1,721,801	1,792,283
Total Assets		1,721,801	1,792,283
Liabilities			
Current Liabilities			
GST Payable		2,980	1,525
Total Current Liabilities		2,980	1,525
Total Liabilities		2,980	1,525
Net Assets		1,718,821	1,790,757
Member's Funds			
Retained Earnings		1,718,821	1,790,757
Total Member's Funds		1,718,821	1,790,757

The accompanying notes form part of these financial statements. These statements should be read in conjunction with the attached compilation report.

Notes to the Financial Statements

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

1. Summary of Significant Accounting Policies

The financial statements are special purpose financial statements prepared in order to satisfy the financial reporting requirements of the *Associations Incorporation Act (Tas) 1964*. The committee has determined that the association is not a reporting entity.

The financial statements have been prepared on an accruals basis and are based on historic costs and do not take into account changing money values or, except where stated specifically, current valuations of non-current assets.

The following significant accounting policies, which are consistent with the previous period unless stated otherwise, have been adopted in the preparation of these financial statements.

Income Tax

The activity of the Association is the provision of medical appliances to members. As such, no provision for income tax has been raised as the entity is exempt from income tax under Div 50 of the *Income Tax Assessment Act 1997*.

Property, Plant and Equipment (PPE)

Leasehold improvements and office equipment are carried at cost less, where applicable, any accumulated depreciation.

The depreciable amount of all PPE is depreciated over the useful lives of the assets to the association commencing from the time the asset is held ready for use.

Leasehold improvements are amortised over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

Impairment of Assets

At the end of each reporting period, the committee reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised in the income and expenditure statement.

Cash on Hand

Cash on hand includes cash on hand, deposits held at call with banks, and other short-term highly liquid investments with original maturities of three months or less.

Accounts Receivable and Other Debtors

Accounts receivable and other debtors include amounts due from members as well as amounts receivable from donors. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

Revenue and Other Income

These notes should be read in conjunction with the attached compilation report.

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. For this purpose, deferred consideration is not discounted to present values when recognising revenue.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Grant and donation income is recognised when the entity obtains control over the funds, which is generally at the time of receipt.

If conditions are attached to the grant that must be satisfied before the association is eligible to receive the contribution, recognition of the grant as revenue will be deferred until those conditions are satisfied.

All revenue is stated net of the amount of goods and services tax.

Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the assets and liabilities statement.

Accounts Payable and Other Payables

Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the association during the reporting period that remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

Officer Bearers & Committee

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

PATRON:

Kate Warner (retired on 9 June 2021)

Barbara Baker (16 June 2021 - present)

PRESIDENT:

Deirdre Tuck

VICE PRESIDENT:

Gregory Woods

SECRETARY:

Annette Ogilvie

TREASURER:

Louisa Docking

COMMITTEE:

Dr Katherine Marsden

Wendy Snell

Graeme Petterd

LIFE MEMBERS:

Dr M Baikie

Mrs J Balon

Mrs B Collins

Mr N Deane

Anne Piaszczyk

Committee's Report

David Collins Leukaemia Foundation of Tasmania Inc For the year ended 31 December 2021

Annual Statements Give True and Fair View of Financial Position and Performance of the Association

- A net loss of \$71,937 was incurred by the foundation in 2021. This was largely associated with the \$55,132 paid for capital donations, as well as a significant increase in payments for Patient Care.
- Donations remained constant in 2021.
- Interest income decreased by \$21,766 in 2021, which was due to the withdrawal of term deposit of \$75,000 during the year.
- Tin collections remained constant in 2021.

**Bentleys Tasmania Audit
Pty Ltd**

2nd Floor, 39 Sandy Bay Road
Hobart 7000

PO Box 205

Battery Point 7004

ABN 80 130 770 553

T +61 3 6242 7000

F +61 3 6278 3555

admin@bentleystas.com.au

bentleys.com.au

**DAVID COLLINS LEUKAEMIA FOUNDATION OF TASMANIA INC
ABN: 24 819 325 355**

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SUB
DIVISION 60-C SECTION 60-40 OF THE AUSTRALIAN CHARITIES
AND NOT-FOR-PROFITS COMMISSION ACT 2012 TO DAVID COLLINS
LEUKAEMIA FOUNDATION OF TASMANIA INC**

I declare that, to the best of my knowledge and belief, during the year ended
31 December 2021 there have been no contraventions of:

- i. the auditor independence requirements as set out in the Australian Charities And Not-for-profits Commission Act 2012 in relation to the audit; and
- ii. any applicable code of professional conduct in relation to the audit.



Michael Ian Derbyshire
Director

Hobart

5 April 2022

**Bentleys Tasmania Audit
Pty Ltd**

2nd Floor, 39 Sandy Bay Road
Hobart 7000

PO Box 205
Battery Point 7004

ABN 80 130 770 553

T +61 3 6242 7000

F +61 3 6278 3555

admin@bentleystas.com.au
bentleys.com.au

**INDEPENDENT AUDIT REPORT
TO THE MEMBERS OF DAVID COLLINS LEUKAEMIA FOUNDATION
OF TASMANIA INC
ABN: 24 819 325 355**

Audit Opinion

We have audited the special purpose financial report of the David Collins Leukaemia Foundation of Tasmania Inc (the Entity), which comprises the balance sheet as at 31 December 2021, the profit and loss statement, cash flow statement and statement of changes in equity for the year then ended, and notes comprising a summary of significant accounting policies and other explanatory notes.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, the accompanying financial report of David Collins Leukaemia Foundation of Tasmania Inc has been prepared in accordance with Division 60 of the Australian Charities and Not-for-Profits Commission Act 2012, including:

- a) giving a true and fair view of the registered entity's financial position as at 31 December 2021, and of its financial performance for the year ended on that date; and
- b) complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for Qualified Opinion

Cash donations are a significant source of revenue for the David Collins Leukaemia Foundation of Tasmania Inc. The entity has determined that it is impracticable to establish control over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding revenue from this source was limited, our audit procedures with respect to cash donations were restricted to the amounts recorded in the financial records.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Entity in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The special purpose financial report has been prepared for the purpose of fulfilling the responsible entities' financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibility of the Responsible Entities for the Financial Report

The Board of Management of the entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The Board's responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Board is responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the Board either intends to liquidate the entity or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit

evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board.
- Conclude on the appropriateness of the Board's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Board regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Michael Ian Derbyshire
Director

5 April 2022

**The Foundation
expresses its**

SINCERE APPRECIATION

**To all donors of money,
effort and time during the year.**

Donations of \$2 or more are TAX DEDUCTIBLE

For further information please contact:
David Collins Leukaemia Foundation of Tasmania
PO Box 372
Hobart Tasmania 7001
Website: <http://www.leukaemia-tasmania.com.au>